H.C. Wainwright analyst Matthew Caufield initiated coverage of DiaMedica Therapeutics with a Buy rating and $7 price target DiaMedica is a clinical stage biopharmaceutical company focused on the treatment of acute ischemic stroke and preeclampsia, the analyst tells investors in a research note. The firm cites expectations for further DM199 validation for stroke recovery outcomes, and utilization in pregnancy, for the Buy rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
Questions or Comments about the article? Write to editor@tipranks.com